Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Holding TVTX?
Track your performance easily
TVTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.12 - $20.33
Previous CloseN/A
Volume140.04K
Average Volume (3M)1.23M
Market Cap
$1.57B
Enterprise Value$1.21B
Total Cash (Recent Filing)$255.87M
Total Debt (Recent Filing)$44.42M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Mar 03, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding87,034,300
10 Day Avg. Volume1,081,172
30 Day Avg. Volume1,227,022
Standard Deviation0.18
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.94
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue5.96
Enterprise Value/Gross Profit9.07
Enterprise Value/Ebitda-5.18
Forecast
1Y Price Target
$30.20Price Target Upside62.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Travere Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical SuccessThe results further enhance confidence in the potential of Filspari becoming a possible first-line therapy for IgAN, as well as the clinical success of the drug in treating FSGS.
Financial Performance4Q net revenues of $50M were up an impressive +40% q/q, with 693 new patient start forms, consistent with accelerating uptake.
Regulatory ApprovalFull Sparsentan approval appears to be driving an acceleration in growth.
Bears Say
Market CompetitionCompetition in the IgAN space is on the horizon with upcoming Ph3 readouts from the APRIL/BAFF class.
Regulatory ApprovalThere is caution on a clear path forward to approval without an additional study.
Regulatory RisksRisks include FDA asking additional analyses from workgroup or evidence of biological plausibility specific to FIlspari MOA.
---
Ownership Overview
1.33% Insiders
20.60% Mutual Funds
0.02% Other Institutional Investors
62.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $5.12 and its highest was $20.33 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $1.57B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 47 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Oct 31, 2024. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.669 by -$0.031.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -0.58.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 87,034,300 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.669. Following the earnings report the stock price went down -1.464%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in TVTX
---
Travere Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.20 (62.45% Upside)
$30.20 (62.45% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.06%
12-Months-Change
Fundamentals
Return on Equity
-279.94%
Trailing 12-Months
Asset Growth
-39.44%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics is focused on developing therapies for rare kidney and metabolic disorders. The biopharmaceutical company's products include FILSPARI (sparsentan), and Thiola and Thiola EC (tiopronin tablets).
---
TVTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook for Travere Therapeutics, with significant advancements in the approval and market expansion of FILSPARI, strong financial growth, and promising regulatory progress for FSGS. However, challenges remain with the pause in pegtibatinase enrollment and reported net loss.Read More>---
TVTX Stock 12 Month Forecast
Average Price Target
$30.20
▲(62.45% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Allogene Therapeutics
―
Fate Therapeutics
―
Arvinas Holding Company
―
MacroGenics
―
Blueprint Medicines
―
Best Analysts Covering TVTX
1 Year
1 Year Success Rate
16/25 ratings generated profit
1 Year Average Return
+22.33%
reiterated a buy rating 3 months ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +22.33% per trade.
---